Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

Item

http://www.wikidata.org/entity/Q36755219

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

@ast

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

@en

type

Item

label

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

@ast

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

@en

prefLabel

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

@ast

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

@en

P1476

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

@en

P2093

H Kosmehl

http://www.w3.org/2001/XMLSchema#string

R Dahse

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.

Epidermal growth factor receptor mutations in lung cancers.

Two allele-specific PCR assays for screening epidermal growth factor receptor gene hotspot mutations in lung adenocarcinoma.

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

P2888

sj.bjc.6604430

P304

90-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604430

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5315488

http://www.w3.org/2001/XMLSchema#string

P698

18542074

http://www.w3.org/2001/XMLSchema#string

P932

2453031

http://www.w3.org/2001/XMLSchema#string